New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19
The Pharma Data
DECEMBER 17, 2020
If the therapy proves safe and effective in clinical trials and regulatory approvals are granted, Regeneron will manufacture and distribute it in the U.S. , and Roche will develop, manufacture and distribute it outside of the U.S. who require oxygen therapy due to COVID-19, OR. AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION.
Let's personalize your content